학술논문
LBA84 - Primary results from TAIL, a global single-arm safety study of atezolizumab (atezo) monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer (NSCLC)
Document Type
Abstract
Author
Source
In Annals of Oncology October 2019 30 Supplement 5:v920-v921
Subject
Language
ISSN
0923-7534